AI Engines For more Details: Perplexity Kagi Labs You
Bacterial Infections: Ticarcillin sodium is effective against a wide range of bacterial infections caused by susceptible organisms. It is commonly used to treat infections such as pneumonia, urinary tract infections, skin and soft tissue infections, intra-abdominal infections, bone and joint infections, and septicemia.
Combination Therapy: Ticarcillin sodium is often combined with clavulanic acid to form the antibiotic combination drug known as Timentin. Clavulanic acid helps to inhibit bacterial Ξ²-lactamases, enzymes that can inactivate ticarcillin, thereby enhancing its antibacterial activity against Ξ²-lactamase-producing bacteria.
Mechanism of Action: Ticarcillin sodium belongs to the penicillin class of antibiotics and works by inhibiting bacterial cell wall synthesis. It does this by binding to and inhibiting the activity of enzymes involved in the cross-linking of peptidoglycan, a major component of bacterial cell walls. This leads to bacterial cell lysis and ultimately death.
Susceptible Organisms: Ticarcillin sodium is effective against a wide range of gram-positive and gram-negative bacteria, including Pseudomonas aeruginosa, Enterobacter species, Escherichia coli, Klebsiella species, Proteus mirabilis, Streptococcus pneumoniae, and many others.
Administration: Ticarcillin sodium is typically administered intravenously (IV) or intramuscularly (IM). It is available in various formulations, including powder for reconstitution and ready-to-use injectable solutions.
Adverse Effects: Common side effects of ticarcillin sodium include gastrointestinal symptoms such as nausea, vomiting, and diarrhea. Allergic reactions, including rash, itching, and swelling, may also occur. Serious adverse effects such as anaphylaxis and pseudomembranous colitis (associated with Clostridium difficile overgrowth) are possible but rare.
Drug Interactions: Ticarcillin sodium may interact with other medications, including probenecid (which can increase ticarcillin levels by reducing renal excretion) and certain anticoagulants (increasing the risk of bleeding).
Renal Impairment: Dose adjustments may be necessary in patients with renal impairment, as ticarcillin is primarily eliminated by the kidneys. Monitoring of renal function and drug levels is recommended in such patients to prevent toxicity.
Pregnancy and Lactation: Ticarcillin sodium should be used with caution during pregnancy and lactation, as its safety profile in these populations has not been well established. The potential benefits of ticarcillin therapy should be weighed against the potential risks to the fetus or infant.
Resistant Organisms: The widespread use of ticarcillin sodium has led to the development of bacterial resistance in some cases. It is essential to use ticarcillin sodium judiciously and according to local antibiotic susceptibility patterns to minimize the emergence of resistant strains.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.6 | 0.9 | -0.5 |
| ADHD | 5.4 | 0.9 | 5 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.7 | 3.5 | 0.06 |
| Allergies | 9.3 | 5.9 | 0.58 |
| Allergy to milk products | 2.6 | 1.6 | 0.63 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 8.9 | 8.3 | 0.07 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 5.2 | 2 | 1.6 |
| Ankylosing spondylitis | 5.3 | 1.8 | 1.94 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 2.1 | 0.3 | 6 |
| Asthma | 6.5 | 3.4 | 0.91 |
| Atherosclerosis | 2.7 | 3.3 | -0.22 |
| Atrial fibrillation | 4.1 | 3.1 | 0.32 |
| Autism | 11.9 | 11.9 | 0 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 3 | 3 | |
| Bipolar Disorder | 2.4 | 1.7 | 0.41 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 1.8 | 0.3 | 5 |
| Cancer (General) | 0.9 | 3.4 | -2.78 |
| Carcinoma | 5.2 | 2.6 | 1 |
| Celiac Disease | 3.6 | 4.3 | -0.19 |
| Cerebral Palsy | 1.9 | 1.3 | 0.46 |
| Chronic Fatigue Syndrome | 6 | 7.7 | -0.28 |
| Chronic Kidney Disease | 5.2 | 3.4 | 0.53 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 3 | 2 | 0.5 |
| Chronic Urticaria (Hives) | 2 | 1.8 | 0.11 |
| Coagulation / Micro clot triggering bacteria | 1.9 | 1.3 | 0.46 |
| Cognitive Function | 4.2 | 1.6 | 1.63 |
| Colorectal Cancer | 11.9 | 3.6 | 2.31 |
| Constipation | 2.7 | 1.6 | 0.69 |
| Coronary artery disease | 3 | 3 | 0 |
| COVID-19 | 12.1 | 15.1 | -0.25 |
| Crohn's Disease | 10.4 | 6.9 | 0.51 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.2 | 1.9 | -0.58 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 4.2 | 1.4 | 2 |
| Denture Wearers Oral Shifts | 2.1 | 2.1 | |
| Depression | 13.4 | 11.6 | 0.16 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.3 | 3.2 | -0.39 |
| Endometriosis | 3.5 | 2.6 | 0.35 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 4.5 | 2.8 | 0.61 |
| erectile dysfunction | 2.6 | 0.3 | 7.67 |
| Fibromyalgia | 3.7 | 3.6 | 0.03 |
| Functional constipation / chronic idiopathic constipation | 6.9 | 4.9 | 0.41 |
| gallstone disease (gsd) | 4.3 | 1.6 | 1.69 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.4 | 1.2 | 1 |
| Generalized anxiety disorder | 3.9 | 3 | 0.3 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 3.2 | 1.9 | 0.68 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 2.6 | -1.89 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 4.4 | 2.3 | 0.91 |
| Heart Failure | 5.6 | 3.3 | 0.7 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1.9 | 0.6 | 2.17 |
| hypercholesterolemia (High Cholesterol) | 1.1 | 0.6 | 0.83 |
| hyperglycemia | 3 | 2.2 | 0.36 |
| Hyperlipidemia (High Blood Fats) | 1.4 | 0.3 | 3.67 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 5.8 | 6.8 | -0.17 |
| Hypothyroidism | 1.4 | 1 | 0.4 |
| Hypoxia | 4.1 | 0.9 | 3.56 |
| IgA nephropathy (IgAN) | 1.9 | 5.5 | -1.89 |
| Inflammatory Bowel Disease | 11.6 | 12.1 | -0.04 |
| Insomnia | 2.8 | 3.5 | -0.25 |
| Intelligence | 2.6 | 0.6 | 3.33 |
| Intracranial aneurysms | 1.4 | 0.9 | 0.56 |
| Irritable Bowel Syndrome | 10 | 6.4 | 0.56 |
| ischemic stroke | 3.7 | 1.7 | 1.18 |
| Liver Cirrhosis | 9.2 | 5.9 | 0.56 |
| Long COVID | 8.1 | 9.3 | -0.15 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.5 | 1.6 | -0.07 |
| Lymphoma | 0.9 | 0.9 | |
| Mast Cell Issues / mastitis | 1.5 | 0.9 | 0.67 |
| ME/CFS with IBS | 0.5 | 2.4 | -3.8 |
| ME/CFS without IBS | 2 | 2.4 | -0.2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 1 | 1.1 |
| Metabolic Syndrome | 9.5 | 9.6 | -0.01 |
| Mood Disorders | 13.4 | 9.5 | 0.41 |
| multiple chemical sensitivity [MCS] | 1.7 | 0.1 | 16 |
| Multiple Sclerosis | 9.6 | 7 | 0.37 |
| Multiple system atrophy (MSA) | 2.3 | 0.7 | 2.29 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.6 | -11 |
| Neuropathy (all types) | 1.2 | 3.1 | -1.58 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.2 | 1.2 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 6.5 | 5.9 | 0.1 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 13.4 | 10.6 | 0.26 |
| obsessive-compulsive disorder | 7 | 4.8 | 0.46 |
| Osteoarthritis | 3.3 | 1.7 | 0.94 |
| Osteoporosis | 3.1 | 2.2 | 0.41 |
| pancreatic cancer | 2.3 | 0.6 | 2.83 |
| Parkinson's Disease | 11.2 | 9.5 | 0.18 |
| Polycystic ovary syndrome | 7.9 | 3.7 | 1.14 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 3 | 3.2 | -0.07 |
| Psoriasis | 4.4 | 4 | 0.1 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 9.6 | 4.7 | 1.04 |
| Rosacea | 1.2 | 1 | 0.2 |
| Schizophrenia | 8.4 | 3.6 | 1.33 |
| scoliosis | 0.9 | 1.2 | -0.33 |
| Sjögren syndrome | 3.2 | 3.2 | 0 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 1.5 | 0.3 | 4 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2.2 | 0.6 | 2.67 |
| Stress / posttraumatic stress disorder | 3.7 | 3.3 | 0.12 |
| Systemic Lupus Erythematosus | 4.9 | 2.4 | 1.04 |
| Tic Disorder | 1.5 | 1.8 | -0.2 |
| Tourette syndrome | 1.4 | 0.3 | 3.67 |
| Type 1 Diabetes | 6.3 | 4.4 | 0.43 |
| Type 2 Diabetes | 9.9 | 9.6 | 0.03 |
| Ulcerative colitis | 7.6 | 10 | -0.32 |
| Unhealthy Ageing | 6.2 | 2.9 | 1.14 |
| Vitiligo | 2.5 | 2 | 0.25 |
